Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis

scientific article published on 28 November 2018

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1126/SCIADV.AAT3834
P932PMC publication ID6261652
P698PubMed publication ID30498775

P50authorMichael W ParkerQ41147578
Angel F. LopezQ42799423
David RossQ42884508
Jeffrey J BabonQ56882450
Timothy R HercusQ62554539
Nicholas P D LiauQ86251815
Denis TvorogovQ89983184
Daniel ThomasQ93379945
P2093author name stringRavindra Majeti
Vinay Tergaonkar
Timothy P Hughes
Winnie L Kan
Emma F Barry
Mara Dottore
Frank Stomski
Maya Lathi
P2860cites workEffective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerizationQ24311715
Identification of a hierarchy of multipotent hematopoietic progenitors in human cord bloodQ24656265
Janus kinase deregulation in leukemia and lymphomaQ26991810
Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode DependentQ27681086
Jak2 is essential for signaling through a variety of cytokine receptorsQ28270987
Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particlesQ33331222
Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosisQ33397838
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisQ33399980
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuationQ33416494
Leukemic diffuse large B-cell lymphoma in a patient with myeloproliferative disorder.Q33420865
Mechanism of activation of protein kinase JAK2 by the growth hormone receptorQ34420222
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.Q34485103
A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses.Q36565214
Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.Q37708936
The JAK-STAT pathway at twentyQ38004201
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosisQ38816577
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapyQ38824881
Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.Q40031223
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disordersQ40330808
JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.Q40960930
Thrombopoietin receptor is required for the oncogenic function of CALR mutants.Q42365043
Ruxolitinib withdrawal syndrome leading to tumor lysisQ44277096
A life-threatening ruxolitinib discontinuation syndromeQ47906964
Recurrent hypoxemic respiratory failure. Beyond the usual suspects.Q51696636
Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin.Q53204648
Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptorsQ78225288
P433issue11
P407language of work or nameEnglishQ1860
P921main subjectmyelofibrosisQ1752571
phosphorylationQ242736
P304page(s)eaat3834
P577publication date2018-11-01
P1433published inScience AdvancesQ19881044
P1476titleAccumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
P478volume4

Reverse relations

cites work (P2860)
Q92354392Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling
Q92340076Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity
Q89682918Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells
Q91198796Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F+ cell models

Search more.